Andrew Maynard

Andrew Maynard has a diverse and extensive work experience in the field of computational chemistry and drug discovery. Andrew is currently serving as the Senior Director of Computational Chemistry at Tango Therapeutics since October 2022. Prior to that, they worked as the Director of Computational Chemistry at Civetta Therapeutics from October 2021 to October 2022.

Before joining Civetta Therapeutics, Maynard held the position of Principal Scientist at Casma Therapeutics from September 2019 to September 2021. Andrew also worked as an Applications Scientist at OpenEye Scientific Software, Inc. from January 2018 to September 2019.

Maynard has also worked as a Drug Hunting Consultant at Creode Analytics, LLC from May 2016 to January 2018, where they focused on drug discovery consulting and computational methods development.

Earlier in their career, Maynard served as a Scientific Program Manager at the National Institute of Environmental Health Sciences (NIEHS) from August 2015 to April 2017, where they managed and supported the Children's Health Exposure Analysis Resource (CHEAR) program.

From 2009 to 2015, Maynard worked at GSK as a Senior Scientific Investigator and Manager, leading and supporting discovery programs in various therapeutic areas. Prior to that, they held the position of Principal Scientist at Icagen from October 2004 to October 2009, where they integrated and utilized computational technologies within a corporate drug discovery platform.

Maynard's work experience also includes being an Investigator at AstraZeneca from October 2000 to October 2004, where they worked on project leadership and support for discovery programs in CNS diseases and developed informatics methods for hit-to-lead identification.

At the start of their career, Maynard served as an NIH Postdoctoral Fellow and Research Scientist at the National Cancer Institute (NCI), where they conducted basic research involving retroviral proteins and nucleocapsid proteins.

Overall, Andrew Maynard's work experience spans across various roles and organizations, contributing to the fields of computational chemistry, drug discovery, and environmental health sciences.

Andrew Maynard has a Doctor of Philosophy (Ph.D.) degree in Chemical Physics from The University of Texas at Austin, a Master of Science (M.S.) degree in Physical Chemistry from the University of North Carolina at Chapel Hill, and a Bachelor of Science (B.Sc.) degree in Chemistry from Tulane University.